<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04669860</url>
  </required_header>
  <id_info>
    <org_study_id>20200100</org_study_id>
    <nct_id>NCT04669860</nct_id>
  </id_info>
  <brief_title>Evaluating the Bacterial and Fungal Microbiome in Patients With Calcium Oxalate Urolithiasis and Renal Cell Carcinoma</brief_title>
  <official_title>Evaluating the Bacterial and Fungal Microbiome in Patients With Calcium Oxalate Urolithiasis and Renal Cell Carcinoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to identify bacterial and fungal microbiome associated with&#xD;
      calcium oxalate (CO) urolithiasis and renal cell carcinoma (RCC).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Microbial community structure in patients with CO urolithiasis</measure>
    <time_frame>Day 1</time_frame>
    <description>Alpha and beta diversity, principal coordinate analysis, and phylogenetic trees of the bacterial and fungal microbial community from mid-stream voided urine sample, urine sample collected from the bladder, kidney stone fragment, and a renal papillae biopsy specimen.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Microbial community structure in patients with RCC</measure>
    <time_frame>Day 1</time_frame>
    <description>Alpha and beta diversity, principal coordinate analysis, and phylogenetic trees of the bacterial and fungal microbial community from catheterized urine specimen from the bladder, a biopsy of the tumor, and a biopsy of normal-appearing renal papillae specimen.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Microbial community structure in healthy participants</measure>
    <time_frame>Day 1</time_frame>
    <description>Alpha and beta diversity, principal coordinate analysis, and phylogenetic trees of the bacterial and fungal microbial community from clean-catch urine specimen.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Calcium Oxalate Urolithiasis</condition>
  <condition>Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>calcium oxalate urolithiasis group</arm_group_label>
    <description>Participants with CO urolithiasis scheduled for definitive endoscopic stone removal will be evaluated to identify bacterial and fungal microbiome in mid-stream voided urine sample, urine sample collected from the bladder, kidney stone fragment, and a renal papillae biopsy specimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>renal cell carcinoma group</arm_group_label>
    <description>Participants with RCC scheduled for definitive kidney removal surgery will be evaluated to identify bacterial and fungal microbiome in a catheterized urine specimen from the bladder, a biopsy of the tumor, and a biopsy of normal-appearing renal papillae specimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy control group</arm_group_label>
    <description>The participants will provide a clean-catch voided midstream urine sample to identify bacterial and fungal microbiome.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      the microbiome of voided urine, bladder urine, stone fragments, and tissue from renal&#xD;
      papillary biopsies in patients with CO stones.&#xD;
&#xD;
      The microbiome of urine from the bladder, tissue from the renal tumor, and tissue from&#xD;
      surrounding healthy renal tissue in patients with RCC&#xD;
&#xD;
      Voided urine sample from healthy volunteers.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        1. Healthy participants&#xD;
&#xD;
          2. Participants with CO urolithiasis scheduled for endoscopic kidney stone removal&#xD;
             surgery.&#xD;
&#xD;
          3. Participants with RCC who are scheduled for kidney removal surgery.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults that are able to consent (â‰¥ 18 years of age)&#xD;
&#xD;
          -  No history of asymptomatic bacteriuria or Urinary Tract Infection within the past 1&#xD;
             month&#xD;
&#xD;
          -  No history of coagulopathy and not on anticoagulant or antiplatelet medication at the&#xD;
             time of surgery.&#xD;
&#xD;
          -  For patients with urolithiasis, must not have a history of RCC&#xD;
&#xD;
          -  For patients with RCC, must not have a history of urolithiasis&#xD;
&#xD;
          -  Controls must have no history of stones, RCC, or urinary tract infection (within 1&#xD;
             month).&#xD;
&#xD;
          -  For all participants, no antimicrobial treatment within the past month&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Adults unable to consent&#xD;
&#xD;
          -  For patients with urolithiasis, technical difficulty in taking renal papillae biopsy.&#xD;
&#xD;
          -  History of urinary tract infection within the past 1 month&#xD;
&#xD;
          -  History of coagulopathy and on anticoagulants or antiplatelets that could not be&#xD;
             stopped perioperatively.&#xD;
&#xD;
          -  Patients with nephrolithiasis and renal tumors with positive preoperative urine&#xD;
             cultures- suggesting asymptomatic bacteriuria.&#xD;
&#xD;
          -  For patients with urolithiasis, a history of RCC&#xD;
&#xD;
          -  For patients with RCC, a history of urolithiasis&#xD;
&#xD;
          -  Controls who have a history of stones, RCC, or urinary tract infection.&#xD;
&#xD;
          -  For all participants, antimicrobial treatment within the past month.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hemendra N Shah</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hemendra N Shah</last_name>
    <phone>3052433246</phone>
    <email>hns35@miami.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hemendra N Shah</last_name>
      <phone>305-243-3246</phone>
      <email>hns35@miami.edu</email>
    </contact>
    <investigator>
      <last_name>Hemendra N Shah</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 10, 2020</study_first_submitted>
  <study_first_submitted_qc>December 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>March 9, 2021</last_update_submitted>
  <last_update_submitted_qc>March 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Hemendra Shah</investigator_full_name>
    <investigator_title>Associate Professor of clinical Urology</investigator_title>
  </responsible_party>
  <keyword>calcium oxalate stones</keyword>
  <keyword>renal cell carcinoma</keyword>
  <keyword>microbiome</keyword>
  <keyword>urinary microbiome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Urolithiasis</mesh_term>
    <mesh_term>Urinary Calculi</mesh_term>
    <mesh_term>Nephrolithiasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

